We have located links that may give you full text access.
TLR7 inhibition: A novel strategy for pancreatic cancer treatment?
JAK-STAT 2013 January 2
PANCREATIC DUCTAL ADENOCARCINOMA IS ASSOCIATED WITH A POOR PROGNOSIS: For local disease, the 5-y survival rate is approximately 20% and median survival in locally advanced disease is only about 10 mo. Carcinogenesis is associated with chronic inflammation showing that innate immunity can be a double-edged sword. Here, we discuss recent findings of Ochi et al. in The Journal of Clinical Investigation who described a novel role for TLR7 in the development and progression of pancreatic cancer through interference with cell cycle regulation and by activation of multiple cell signaling pathways. Of note, inhibition of TLR7 signaling in a mouse p48Cre;Kras(G12D) pancreatic cancer model protected against tumor progression thus paving the road for TLR-blocking strategies to combat tumors.
Full text links
Related Resources
Trending Papers
Executive Summary: State-of-the-Art Review: Unintended Consequences: Risk of Opportunistic Infections Associated with Long-term Glucocorticoid Therapies in Adults.Clinical Infectious Diseases 2024 April 11
Autoimmune Hemolytic Anemias: Classifications, Pathophysiology, Diagnoses and Management.International Journal of Molecular Sciences 2024 April 13
Clinical practice guidelines on the management of status epilepticus in adults: A systematic review.Epilepsia 2024 April 13
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app